Marginal zone (MZ) B cells contain a large number of autoreactive clones and the expansion of this compartment has been associated with autoimmunity. MZ B cells also efficiently transport blood-borne antigen to the follicles where they activate T cells and differentiate into plasma cells. Using the B6.NZM2410.Sle1.Sle2.Sle3 (B6.TC) model of lupus, we show that the IgM þ CD1d hi /MZ B-cell compartment is expanded, and a large number of them reside inside the follicles. Contrary to the peripheral B-cell subset distribution and their activation status, the intrafollicular location of B6.TC IgM þ
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hi /MZ B cells depends on both bone marrow-and stromal-derived factors. Among the factors responsible for this intrafollicular location, we have identified an increased response to CXCL13 by B6.TC MZ B cells and a decreased expression of VCAM-1 on stromal cells in the B6.TC MZ. However, the reduced number of MZ macrophages observed in B6.TC MZs was independent of the IgM þ CD1d hi /B-cell location. B7-2 but not B7-1 deficiency restored IgM þ CD1d hi /MZ B-cell follicular exclusion in B6.TC mice, and it correlated with tolerance to dsDNA and a significant reduction of autoimmune pathology. These results suggest that follicular exclusion of IgM þ CD1d hi /MZ B cells is an important B-cell tolerance mechanism, and that B7-2 signaling is involved in breaching this tolerance checkpoint. The marginal zone (MZ) is an anatomically distinctive region surrounding the follicles in the spleen, and it is composed mostly of B cells, specialized macrophages (marginal zone macrophages, MZMs), and stromal cells, but very few T cells. 1 The location of MZ B cells puts them on the first line of defense against blood-borne pathogens, and they possess unique properties to accomplish this function. 2 MZ B cells are long lived and noncirculating, and they respond to a wide spectrum of T-dependent (TD) and T-independent (TI) antigens by migrating into the follicle, where they can activate naive T cells more efficiently than follicular B cells and quickly differentiate to plasma cells. 3, 4 The location of MZ B cells results from the integration of many factors. Circulating B cells express high levels of CXCR5 that direct them to the follicular B-cell area, where CXCL13 is highly expressed. 5 In spite of their CXCR5 expression, MZ B cells are retained in the MZ through their surface expression of LFA-1 and a4/b1 binding to ICAM-1 and VCAM-1, both expressed at high levels by the MZ stromal cells. 6 MZ B cells also express high levels of the sphingosine 1-phosphate (S1P) receptors S1P 1 and S1P 3 that are quickly downregulated upon antigen encounter, releasing MZ B cells toward the follicles. 7, 8 MZMs also retain B cells in the MZ through contact by the scavenger receptor MARCO. 9 Conversely, MZ B cells are also necessary for the retention and maintenance of MZMs. 10 The MZ B-cell compartment, which is enriched with autoreactive specificities, [11] [12] [13] is expanded in the (NZB Â NZW)F 1 (BWF1) murine model of lupus, 14 and this expansion has been implicated in lupus pathogenesis. [15] [16] [17] Moreover, the massive enlargement of the MZ B-cell compartment resulting from BAFF overexpression is associated with a lupus-like phenotype. 18 We have recently characterized a BWF1-derived NZM strain, TAN, which does not produce anti-dsDNA IgG antibodies (Abs) and is protected from lupus nephritis in spite of the presence of the three NZM2410-Sle lupus susceptibility loci. 19 Interestingly, TAN mice present an enlarged nonfunctional MZ B-cell compartment that expresses high level of CD5, 19 a marker that has been associated with tolerance in anergic B cells, 20 indicating a correlation between tolerization of MZ B cells and disease protection. Also in the NZM model, high affinity anti-DNA Ab producing B cells co-expressing the Sle2 locus and the transgenic 56R immunoglobulin heavy chain that break tolerance to nuclear antigens are heavily skewed toward the MZ compartment. 21 Sequestration of autoreactive B cells into the MZ area has been proposed as a mechanism to prevent autoimmunity, 16 with this process being inefficient in lupus-prone MRL.lpr mice. 22 The goal of this study was to examine the MZ B-cell compartment in the NZM2410-derived B6.NZM2410-Sle1. Sle2.Sle3 (B6.TC) lupus model. 23 We have previously shown that the MZ is greatly reduced to absent in both NZM2410 and B6.TC, and that it contains very little B cells, although the percentage of cells that express MZ B surface markers is higher in these two strains than in the nonautoimmune control strain C57BL/6 (B6). 19 We have now explored these apparently contradictory observations in the B6.TC strain, which presents the advantage of developing fully penetrant lupus nephritis with only about 6% of the NZM2410 genome, and therefore allows the use of H-2 b -matched B6 as a valid experimental control. We found that the B6.TC MZ not only lacks B cells but also MZMs, and that the B6.TC B cells that express CD1d hi , a surface marker expressed on the great majority of B6.TC MZ B, are largely located inside the follicles. This CD1d hi B-cell population presents the same characteristics as that of normal MZ B cells after LPS exposure. 24 The intrafollicular location of the B6.TC CD1d hi / MZ B cells could be explained at least partially by their enhanced migration to CXCL13 and S1P, whereas the MZ area expressed lower levels of VCAM-1. We also showed that the intrafollicular location of B6.TC CD1d hi /MZ B cells depends on both bone marrow (BM) and stromal factors. In addition, we found that B7-2, but not B7-1 deficiency, restored a normal to increased CD1d hi B-cell population in the B6.TC MZ area as well as a dramatic reduction in autoimmune pathology. This latter result strongly suggests that B7-2 signaling is involved in the intrafollicular location of CD1d hi /MZ B cells and it is involved in autoimmune pathology.
MATERIALS AND METHODS Mice
The production of the triple congenic B6.TC (listed in the JAX s mice database as BcN/LmoJ) and CD80 (B7-1) or CD86 (B7-2)-deficient B6 mice has been previously described. 23, 25 For the production of B6.TC.B7-1 À/À and B6.TC.B7-2
À/À
, homozygosity at the Sle1, Sle2, and Sle3 loci as well as the B7-1 and B7-2 null alleles was detected by PCR as previously described. 23, 25 B6 and C57BL/6J-Cg-IghaThy1aGpila/J (B6.IgH a ) mice were obtained from the Jackson Laboratories and bred at the University of Florida. All experiments were conducted according to protocols approved by the University of Florida Institutional Animal Care and Use Committee. Both male and female mice were used in approximately equal numbers with sex-and age-matched B6 controls at 6-to 9-month old, or at 2-3 months when indicated.
Flow Cytometry
Splenocytes were stained with fluorochrome-or biotin-conjugated monoclonal Abs against B220 (RA3-6B2), CD1d (3C11), CD4 (RM4-5), CD5 (53-7. 
Immunofluorescence Staining
Cold acetone-fixed 7 mm frozen spleen sections, first blocked with 10% rat serum, were stained with fluorochrome-or biotin-conjugated Abs: anti-mouse metallophilic macrophage (MOMA-1; Serotec), SIGN-R1 (ER-TR9; BMA Biomedicals), B220 (RA3-6B2), CD1d (1B1), CD5 (53-7.3), IgM (II/41), ICAM (3E2), VCAM-1 (429) and anti-TNP (G235-2356) (all from BD Pharmingen), and CD21 (7E9). Biotinylated Abs were detected with streptavidin-Alexia 568 (Molecular Probes). Sections were then mounted with Prolong Gold Mounting Media (Molecular Probes) and analyzed with a Zeiss Axiom fluorescent microscope.
Bone Marrow Chimeras
Reciprocal BM chimeras between B6.TC and B6.IgH a were performed as previously described. 26 Briefly, Septra (sulfamethoxazole and trimethoprim; Hi-Tech Pharmaceutical)-treated 2-month-old recipient mice were irradiated twice with 525 rad 1 Â 10 7 T cell-depleted BM cells from 4 to 6 week old mice were tail-vein injected in each irradiated mouse. Recipient mice were maintained for 3-8 months, as indicated, before analysis. 
Migration Assay
For each sample, 1 Â 10 6 splenocytes were first equilibrated in culture medium (10 mM HEPES, 10% FCS, 1 Â Pen/Strep in RPMI 1640) in the upper chamber of 5 mm of microporous transwell plates (Corning) for 1 h at 371C. Then 100 ng/ml recombinant mouse CXCL13 (R&D Systems) or 1 nM S1P (Cayman Chemical) was added to the lower chamber. Flow cytometry analysis was conducted on cells migrated to the lower chamber after 2 h as well as on the original input cells to calculate the migration ratio.
In Vivo and In Vitro MZ B-Cell Ficoll Binding Assay For in vivo assays, mice were killed 30 min after i.p. injection with 30 mg TNP-Ficoll (Biosearch). Anti-TNP Ab revealed Ficoll uptake on spleen frozen sections. For in vitro assays, splenocytes were incubated with TNP-Ficoll for 30 min at 371C. Flow cytometry analysis was then conducted on thoroughly washed cells. For the LPS mobilization assay, mice were killed 3 h after i.p. injection with 10 mg LPS and CD1d hi B-cell location was determined by immunofluorescence on splenic frozen sections.
Antibody Measurements
Anti-dsDNA and chromatin IgG auto-Abs, total IgM, and IgG levels were detected by ELISA assays as previously described. 23 Relative units of anti-dsDNA and anti-chromatin IgG were standardized using an NZM2410 serum, setting the reactivity of a 1:100 dilution of this control serum to 100 units.
Splenic and Renal Histology
The evaluation of glomerular lesions used a classification based on modifications of the WHO and RPS/ISN Classification of Glomerulonephritis in Systemic Lupus Erythematosus with a semiquantitative overlay on a 0-4 scale, as previously detailed. 27 Immune complexes in the kidneys were visualized on 8 mM frozen sections stained with FITC-conjugated anti-C3 (Cappel) and anti-IgG g chain (Jackson Immunoresearch). Staining intensity was evaluated in a blind fashion on a semiquantitative 0-3 scale and averaged on at least 10 glomeruli per section. Detection of glomerular macrophages was performed by averaging the number of CD68 þ (Serotec) cells in 10 randomly selected high-power fields. 27 MZ thickness was evaluated on hematoxylin and eosin (H&E) spleen sections comparatively to B6. MZ thickness in B6 mice is 5±1 cell layers (mean and standard deviation, N ¼ 10). MZ 'reduced' was scored as when MZs averaged three cell layers or less on at least 10 follicles, and MZ 'hyperplasia' when this average was seven cell layers or more. Mice were scored as MZ 'normal' when their MZ averaged 4-6 cell layers.
Statistical Analysis
Data were analyzed with the GraphPad Prism 4 software. Parametric or nonparametric were used as indicated, depending on whether the data was normally distributed. For multiple comparisons, ANOVA was used and selected pair comparisons were computed using the appropriate correction. Correlations were evaluated with the F statistic testing the null hypothesis that the linear regression slope was equal to 0. Distributions between two groups were compared using w 29, 30 and about 50% of them are CD21 þ CD23 À in our B6 mice (Figure 1c) . Interestingly, this proportion was significantly higher in B6.TC mice, reaching over 80% (Figure 1c) . These B cells did not express AA4.1 and CD5 (Figure 1d) , and therefore displayed all the classical surface markers that have been described on MZ B cells.
In spite of the increased size of the MZ B compartment, B6.TC IgM þ or IgM þ CD1d hi cells were absent or greatly reduced in the MZ area outside the MOMA-1 þ layer that lines the marginal sinus (Figure 2a) . The majority of these cells, however, were located inside the B6.TC follicles, which were comparatively devoid of follicular B cells (Figure 2b ). Given (1) the expanded MZ B population characterized by surface markers, (2) (Figure 3a) , and reduced follicular B-cell subset (data not shown). However, the size of the MZ B compartment was significantly reduced in B cells of B6.TC origin (either transferred into B6.TC or B6 recipients), which contrasted with unmanipulated mice in which the percentage of B6.TC MZ B cells was increased (Figures 1 and 3b) . The same results were obtained at either 3 months (Figure 3 location in 3 month chimeras, the disorganization of the B6.TC follicular structure results from both BM-and stromal-derived factors. Interestingly, the paucity of B6.TC MZMs was entirely BM-derived (Figure 3d ) and was dissociated from retention of IgM þ CD1d hi /MZ B cells in the MZ area. MZM numbers and distribution in both B6 and B6.TC control syngeneic chimeras were similar to that of the corresponding unmanipulated mice (data not shown). This suggested that contrary to gene-targeted models, 9, 10 MZMs and MZ B cells are not dependent on each other for MZ location in the B6.TC model.
B6.TC MZ B Cells are Functionally Defective
To assess B6.TC MZ B-cell function, we analyzed their in vivo ability to bind TNP-Ficoll, a TI type 2 (TI-2) antigen used as a model for blood-borne Gram þ bacteria. TNP-Ficoll binding was intense and confined to the B6 MZ, but it was sparser in the B6.TC MZ area and scattered in the follicles (Figure 4a ). To control for accessibility of the B6.TC intrafollicular MZ B cells to blood flow, splenocytes were exposed in vitro to graded concentrations of TNP-Ficoll and TNP binding was assessed by flow cytometry. As expected, TNP binding was only found in IgM þ CD21 þ CD23 À B cells in both strains (data not shown). Even at the lowest Ficoll concentration (r5 mg/ml), significantly fewer B6.TC MZ B cells bound TNP than B6 (Po0.01), and the difference between the two dose-responses was highly significant (Po0.0001, Figure 4b Figures 2b and 4d) . MZ B cells respond rapidly to LPS due to their high expression of the TLR4 complex. 32 As expected, the expression of the MD-1/RP105 component of TLR4 was much greater on B6 IgM 
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hi B cells showed increased migration to S1P (Figure 5f ). Overall, these data suggest that decreased VCAM-1 expression by MZ stromal cells combined with increased migration to CXCL13 and S1P account, at least in part, for the intrafollicular location of B6.TC MZ B cells. BAFF-R expression, which is high on MZ B cells, 33 was significantly higher on B6.TC than on B6 IgM þ CD1d hi B cells (Figures 5g and h ). This was however not specific to MZ B cells as BAFF-R expression was also significantly higher on total B6.TC B cells as compared to B6 (Po0.05). Increased BAFF-R expression by B6.TC B cells may result from increased BCR signaling, 34 and/or reflect that autoreactive B cells require more BAFF for survival, 35 but it is unlikely to account for the specific MZ B phenotypes in B6.TC mice. (Figure 6a ) and anti-chromatin IgG (data not shown) and significantly reduced the production of total IgG (Figure 6b ) but not IgM (data not shown) in B6.TC mice. Renal pathology was significantly reduced by both B7-1 and B7-2 deficiency (Figures 6c-f ), but this improvement was significantly greater in B6.TC.B7-2 À/À mice. CD23 expression on B cells was also increased by both B7-1 and B7-2 deficiency (Figure 6g ), but B7-2 deficiency had a more profound effect, as B6.TC.B7-2 À/À mice had a normal CD23 þ follicular B-cell compartment as detected both by flow cytometry (data not shown) and by immunohistochemistry (Figure 7a) . A well-developed MZ B population was also apparent in B6.TC.B7-2 À/À but not in B6.TC.B7-1 À/À spleens. In fact, more than 50% of the B6.TC.B7-2 À/À splenic H&E sections revealed an MZ thickness equivalent to B6, and over 40% of them were hyperplastic. This was significantly different from B6.TC, in which 98% of the spleens showed reduced MZ thickness (Figure 6h (Figures 5b and c) . Finally, normal numbers and location of ETR9 þ MZMs were also restored by B7-2 but not B7-1deficiency (Figure 7c ). These results indicate that increased B7-2 activation is involved in the abnormal B6.TC IgM þ CD1d hi /MZ B phenotypes. B7-2 expression was higher on total B6.TC B cells than in B6 (Morel et al 23 ; data not shown), but it was similar between ex vivo B6.TC and B6
þ MZ B cells, although high levels of in vitro anti-IgM stimulation induced a significantly higher B7-2 expression on B6.TC MZB cells (Supplementary Figure 2) . The other activation markers CD80 and CD69 were also expressed at similar levels between B6.TC and B6 MZ B cells (data not shown). DISCUSSION B6.TC mice show an abnormal splenic B-cell development with a striking proportional decrease in CD23 þ B cells that is correlated with autoantibody production and T-cell activation. We have previously shown that transitional T1 B cells, which are CD23 À , accumulate in B6.TC spleens, 19, 27 suggesting a defect in the check point that eliminates the large number of autoreactive clones emerging from the BM. 36 We have shown that MZ B cells, the other CD23 À B-cell subset apart from plasma cells, represent an increased percentage of splenic B cells in B6.TC mice as compared to B6 (Duan et al and Xu et al 19, 27 and this report). An enlargement of the MZ B-cell compartment has been described and implicated in murine models of lupus, [14] [15] [16] [17] and type I diabetes. 30 What sets the B6.TC MZ B cells apart is their intrafollicular location. MZ B cells are more potent T-cell activators that respond more rapidly than follicular B cells to TD antigens, 3 and are essential role in transporting antigens to the follicle. 37 MZ B cells also differentiate rapidly into plasma cells in response to either TD 37 The fact that B6.TC.B7-2 À/À MZ B cells express high CXCR5 levels, but respond poorly to CXCR13 is still consistent with this hypothesis, but the discrepancy between receptor expression and response to the chemokine will have to be addressed in that strain. In normal MZ B cells, CXCR5 response to CXCL13 is abrogated by other factors. LFA-1 and a4b1 integrins expressed by B cells interact with ICAM-1 and VCAM-1, respectively on stromal cells to direct B cells to the white pulp. 41 MZ B cells express higher levels of LFA-1 and a4b1 than follicular B cells, and ablation of integrin binding causes the release of MZ B cells to the peripheral blood. 6 B6.TC IgM þ CD1d hi /MZ B cells express a slightly higher LFA-1 level than B6 that may indicate a higher level of BCR activation. 42 However, immunofluorescence staining suggested a high VCAM-1 expression in B6 MZ but a uniformly lower VCAM-1 expression across B6.TC white pulp. Overall, this is predicted to result in a greater scattering of B6.TC IgM þ CD1d hi /MZ B cells, which were less retained in the MZ. Another factor that abrogates MZ B-cell migration to CXCL13 are the S1P receptors, which are expressed at higher levels on MZ B cells than on follicular B cells, and therefore prevent them from entering the follicles. 7,37 MZ B cells from mice lacking both CXCL13 and S1P receptors did not migrate to the follicles in response to antigen stimulation, 7 suggesting an important balance among integrins, S1P, and CXCL13. An important clue provided by this study was that B7-2 but not B7-1 deficiency restored normal MZ B-cell location as well as nuclear antigen tolerance and significantly reduced renal pathology in the B6.TC mouse. Only the targeting of both B7-1 and B7-2 with either blocking Abs or genetic engineering was able to offer a significant protection from clinical disease in the MRL/lpr model, with a relatively greater impact of B7-2 deficiency on autoantibody production. 46 The B7-1 and B7-2 molecules bind preferentially to CTLA-4 and CD28, respectively, [47] [48] [49] [50] and B7-1 also binds to the negative regulator PDL-1. 51 The exact mechanism by which B7-2 deficiency protects B6.TC mice from autoimmune pathogenesis will require the separate evaluation of the various cell types in which this co-stimulatory molecule is expressed. B7-2 but not B7-1 is upregulated on MZ B cells after BCR engagement, 4 but B7-2 expression on IgM þ CD1d hi /MZ B cells was equivalent between B6.TC and B6. Moreover, we did not observe the BCR-dependent expansion of a B7-2 hi of B6.TC MZ B population as described in NZB mice. 52 These results indicate that that B7-2 does not affect the B6.TC MZ B-cell phenotypes directly through its overexpression. B7-2 activation induces B-cell proliferation and immunoglobulin secretion, at least in part through increasing the expression of Bcl-w and Bcl-xL and decreasing capase-8 expression.
53 B7-2 signaling also increases the NF-kB, PI3K, PLCg2, and PKCab pathways in B cells, 54, 55 each of which is highly activated in B cells in our model, 45 suggesting that at least one of these pathways is responsible for the B6.TC IgM þ CD1d hi /MZ B intrafollicular location. We hypothesize that the absence of B7-2 signaling resets a pathway that is aberrant in B6.TC MZ B cells due to yet unknown primary defects. None of the individual Sle loci is sufficient to induce MZ B-cell intrafollicular location (L Morel, unpublished), which indicates a complex mechanism requiring interactions of multiple genetic defects.
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